Are HIV-infected men vulnerable to prostate cancer treatment disparities? - Test2 - elhamkhani - TriplyDB

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

http://www.wikidata.org/entity/Q34288005

about

Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer.Racial differences in prostate cancer risk in young HIV-positive and HIV-negative men: a prospective cohort study.Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (HIV)-positive population: experience in an Australian major HIV centre.Cancer survival in people with aids: A population-based study from São Paulo, Brazil.Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men: A Review.

P2860

Q38869548-B7A27B76-CDD7-4757-9AD7-4E4E0F456605 Q40223990-21320D95-42B5-4D24-BB26-A537B7CEEEB0 Q40598881-04838C59-B202-4953-876E-A06DA606C85C Q41991826-F7898D74-5FFE-407A-8B40-DB1C6F8252BE Q45762424-70BC2205-B9F5-45E5-A146-0BD40E32302E

P2860

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

http://www.wikidata.org/entity/Q34288005

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@ast

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@en

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@nl

type

label

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@ast

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@en

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@nl

prefLabel

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@ast

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@en

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@nl

P1433

Q34288005-BD356A4C-AC32-49EC-B0BA-889F5342D416

P1476

Q34288005-94EC46EC-E35F-4A8C-805F-48C4071471EB

P2093

Q34288005-0121C89C-3B70-4DCF-BA63-87086FA19789

Q34288005-2727ECE7-5B9C-4237-907C-FD5F37AF3215

Q34288005-4E4443CA-F4FD-46B8-9DEC-E03C6FA55A35

Q34288005-8FADB02B-719C-47E4-A8B3-B21C6C915F17

Q34288005-B311378B-B6D3-45C9-8FDC-43F8ABBB81ED

Q34288005-D32E5787-CECB-4EE9-BA37-61B3C7C1EC79

Q34288005-D662702F-66CF-4A54-9B33-C58D5548DAAA

P2860

Q34288005-059369D0-803D-4226-8151-FA79655410DB

Q34288005-05B0EE66-DEAA-4C39-869B-47E43CF040C4

Q34288005-090A4EAD-1911-4162-B5AE-49529F83BBCE

Q34288005-09C4A2B0-1F28-4F0C-846E-4925C8E4829D

Q34288005-0BA7A6C9-3CE6-496A-A0CC-33E1F7D1D90B

Q34288005-107C0A71-0990-4BAF-806D-25C71609569A

Q34288005-10C59989-EAA3-4308-899A-EB6F33CAB133

Q34288005-182D3662-B09F-4238-9862-19FBC1C158C8

Q34288005-1891FCEA-A81C-4E8B-8A3E-202FBC1BBCAC

Q34288005-1D18E0A3-FDBB-426F-B3E0-B96E66B7C2B3

P304

Q34288005-ACC0ADE7-B6E6-4B65-8F20-A9639070D7FB

P31

Q34288005-B1DE16A7-D4BA-45BD-93DA-6098C5C7C259

P356

Q34288005-DE224A85-9FFD-4FB9-81F4-DCBAA39B3DBE

P433

Q34288005-1C49D47D-A596-439F-9473-F8D1B24A18C0

P478

Q34288005-41D00589-97F6-4E3D-BFAD-C1F80291FD74

P50

Q34288005-35338ECB-1970-4033-8E6F-0C5039456C69

Q34288005-3A183334-87B5-42FA-B49E-D83AC39EEAF7

P577

Q34288005-2C4F6DD4-6849-4898-BABE-8E2F1CF1E18D

P698

Q34288005-94AC3825-B045-4424-9E4A-00DBBD6BE6CD

P932

Q34288005-B0940716-BAAC-4957-9DB4-410C31971AA5

P356

1055-9965.EPI-14-0614

P1433

Cancer Epidemiology, Biomarkers & Prevention

P1476

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

@en

P2093

Adam B Murphy

http://www.w3.org/2001/XMLSchema#string

Courtney M P Hollowell

http://www.w3.org/2001/XMLSchema#string

David A Klein

http://www.w3.org/2001/XMLSchema#string

Elodi Dielubanza

http://www.w3.org/2001/XMLSchema#string

Iman K Martin

http://www.w3.org/2001/XMLSchema#string

Ramona Bhatia

http://www.w3.org/2001/XMLSchema#string

Rick A Kittles

http://www.w3.org/2001/XMLSchema#string

P2860

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Long-term functional outcomes after treatment for localized prostate cancer.

Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States).

Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.

Race, healthcare access and physician trust among prostate cancer patients

Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment.

Radical prostatectomy or watchful waiting in early prostate cancer.

Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview.

How to measure comorbidity. a critical review of available methods.

P304

2009-2018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1055-9965.EPI-14-0614

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25063519

http://www.w3.org/2001/XMLSchema#string

P932

4184974

http://www.w3.org/2001/XMLSchema#string